Literature DB >> 21546584

Stenotrophomonas maltophilia strains replicate and persist in the murine lung, but to significantly different degrees.

Ruella Rouf1, Sara M Karaba1, Jenny Dao1, Nicholas P Cianciotto1.   

Abstract

The environmental bacterium Stenotrophomonas maltophilia is increasingly described as a multidrug-resistant pathogen of humans, being associated with pneumonia, among other diseases. But the degree to which S. maltophilia is capable of replicating in a mammalian host has been an issue of controversy. Using a model of intranasal inoculation into adult A/J mice, we now document that S. maltophilia strain K279a, the clinical isolate of S. maltophilia whose complete genome sequence was recently determined, is in fact capable of replicating in lungs, displaying as much as a 10-fold increase in c.f.u. in the first 8 h of infection. Importantly, as few as 10(4) c.f.u. deposited into the A/J lung was sufficient to promote bacterial outgrowth. Bacterial replication in the lungs of the A/J mice was followed by elevations in pro-inflammatory cytokines and also promoted resistance to subsequent challenge. We also found that DBA/2 mice were permissive for S. maltophilia K279a replication, although the level of growth and persistence in these animals was less than it was in the A/J mice. In contrast, the BALB/c and C57BL/6 mouse strains were non-permissive for S. maltophilia K279a growth. Interestingly, when five additional clinical isolates were introduced into the A/J lung, marked differences in survival were observed, with some strains being much less infective than K279a and others being appreciably more infective. These data suggest that the presence of major virulence determinants is variable among clinical isolates. Overall, this study confirms the infectivity of S. maltophilia for the mammalian host, and illustrates how both host and bacterial factors affect the outcome of Stenotrophomonas infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21546584      PMCID: PMC3167887          DOI: 10.1099/mic.0.048157-0

Source DB:  PubMed          Journal:  Microbiology (Reading)        ISSN: 1350-0872            Impact factor:   2.777


  53 in total

1.  SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.

Authors:  María B Sánchez; José L Martínez
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

2.  Cytotoxic activity of clinical Stenotrophomonas maltophilia.

Authors:  P M S Figueirêdo; M T Furumura; A M Santos; A C T Sousa; D J Kota; C E Levy; T Yano
Journal:  Lett Appl Microbiol       Date:  2006-10       Impact factor: 2.858

Review 3.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

4.  The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of Legionella pneumophila infection.

Authors:  Dario S Zamboni; Koichi S Kobayashi; Tiana Kohlsdorf; Yasunori Ogura; E Michelle Long; Russell E Vance; Keisuke Kuida; Sanjeev Mariathasan; Vishva M Dixit; Richard A Flavell; William F Dietrich; Craig R Roy
Journal:  Nat Immunol       Date:  2006-01-29       Impact factor: 25.606

5.  Cystic fibrosis in adults.

Authors:  Ilma Aparecida Paschoal; Wander de Oliveira Villalba; Carmen Sílvia Bertuzzo; Elza Maria F P Cerqueira; Mônica Corso Pereira
Journal:  Lung       Date:  2007-02-09       Impact factor: 2.584

6.  Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer.

Authors:  Shoaib R Ansari; Hend Hanna; Ray Hachem; Ying Jiang; Kenneth Rolston; Issam Raad
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

7.  Molecular characterization of virulence determinants of Stenotrophomonas maltophilia strains isolated from patients affected by cystic fibrosis.

Authors:  G Di Bonaventura; G Prosseda; F Del Chierico; S Cannavacciuolo; P Cipriani; A Petrucca; F Superti; M G Ammendolia; C Concato; E Fiscarelli; M Casalino; R Piccolomini; M Nicoletti; B Colonna
Journal:  Int J Immunopathol Pharmacol       Date:  2007 Jul-Sep       Impact factor: 3.219

Review 8.  Community-acquired Stenotrophomonas maltophilia infections: a systematic review.

Authors:  M E Falagas; A C Kastoris; E K Vouloumanou; G Dimopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-02-18       Impact factor: 3.267

9.  Pulmonary clearance and inflammatory response in C3H/HeJ mice after intranasal exposure to Pseudomonas spp.

Authors:  S E George; M J Kohan; M I Gilmour; M S Taylor; H G Brooks; J P Creason; L D Claxton
Journal:  Appl Environ Microbiol       Date:  1993-11       Impact factor: 4.792

10.  Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.

Authors:  Kenichiro Shimizu; Ken Kikuchi; Takashi Sasaki; Namiko Takahashi; Masayuki Ohtsuka; Yuka Ono; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

View more
  18 in total

1.  Stenotrophomonas maltophilia Encodes a VirB/VirD4 Type IV Secretion System That Modulates Apoptosis in Human Cells and Promotes Competition against Heterologous Bacteria, Including Pseudomonas aeruginosa.

Authors:  Megan Y Nas; Richard C White; Ashley L DuMont; Alberto E Lopez; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2019-08-21       Impact factor: 3.441

2.  Type II Secretion-Dependent Degradative and Cytotoxic Activities Mediated by Stenotrophomonas maltophilia Serine Proteases StmPr1 and StmPr2.

Authors:  Ashley L DuMont; Sara M Karaba; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2015-07-13       Impact factor: 3.441

3.  Cooperativity between Stenotrophomonas maltophilia and Pseudomonas aeruginosa during Polymicrobial Airway Infections.

Authors:  Melissa S McDaniel; Trenton Schoeb; W Edward Swords
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

4.  Phosphoglycerate mutase affects Stenotrophomonas maltophilia attachment to biotic and abiotic surfaces.

Authors:  Layla Ramos-Hegazy; Shubham Chakravarty; Gregory G Anderson
Journal:  Microbes Infect       Date:  2019-08-17       Impact factor: 2.700

5.  Alterations of lung microbiota in a mouse model of LPS-induced lung injury.

Authors:  Valeriy Poroyko; Fanyong Meng; Angelo Meliton; Taras Afonyushkin; Alexander Ulanov; Ekaterina Semenyuk; Omar Latif; Vera Tesic; Anna A Birukova; Konstantin G Birukov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-05-08       Impact factor: 5.464

6.  Stenotrophomonas maltophilia encodes a type II protein secretion system that promotes detrimental effects on lung epithelial cells.

Authors:  Sara M Karaba; Richard C White; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

7.  Functional characterization of the RNA chaperone Hfq in the opportunistic human pathogen Stenotrophomonas maltophilia.

Authors:  Emanuela Roscetto; Tiziana Angrisano; Valerio Costa; Mariassunta Casalino; Konrad U Förstner; Cynthia M Sharma; Pier Paolo Di Nocera; Eliana De Gregorio
Journal:  J Bacteriol       Date:  2012-08-24       Impact factor: 3.490

8.  Laboratory culture and maintenance of Stenotrophomonas maltophilia.

Authors:  Osama Mahdi; Bridget Eklund; Nathan Fisher
Journal:  Curr Protoc Microbiol       Date:  2014-02-06

9.  Stenotrophomonas maltophilia produces an EntC-dependent catecholate siderophore that is distinct from enterobactin.

Authors:  Megan Y Nas; Nicholas P Cianciotto
Journal:  Microbiology       Date:  2017-10-06       Impact factor: 2.777

10.  Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia.

Authors:  Monika Kumaraswamy; Leo Lin; Joshua Olson; Ching-Fang Sun; Poochit Nonejuie; Ross Corriden; Simon Döhrmann; Syed Raza Ali; Deirdre Amaro; Manfred Rohde; Joe Pogliano; George Sakoulas; Victor Nizet
Journal:  J Antimicrob Chemother       Date:  2016-01-31       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.